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Abstract
The long-term spontaneous evolution of humans and the human immunodeficiency virus (HIV) is not well characterized; many vertebrate
species, including humans, exhibit remnants of other retroviruses in their genomes that question such possible endogenization of HIV.
We investigated two HIV-infected patients with no HIV-related disease and no detection with routine tests of plasma HIV RNA or
cell-associated HIV DNA. We used Sanger and deep sequencing to retrieve HIV DNA sequences integrated in the human genome and
tested the host humoral and cellular immune responses. We noticed that viruses from both patients were inactivated by the high
prevalence of the transformation of tryptophan codons into stop codons (25% overall (3–100% per gene) and 24% overall (0–50% per
gene)). In contrast, the humoral and/or cellular responses were strong for one patient and moderate for the other, indicating that a
productive infection occurred at one stage of the infection. We speculate that the stimulation of APOBEC, the enzyme group that
exchanges G for A in viral nucleic acids and is usually inhibited by the HIV protein Vif, has been amplified and made effective from the
initial stage of the infection. Furthermore, we propose that a cure for HIV may occur through HIV endogenization in humans, as
observed for many other retroviruses in mammals, rather than clearance of all traces of HIV from human cells, which defines viral
eradication.
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Introduction
Human immunodeficiency virus (HIV) is one of the three
‘big killers’ and causes 35 million infections worldwide [1].
Despite massive efforts, attempts to cure people infected with
this virus have failed [2,3], except for an adult HIV-positive
patient who exhibited long-term aviraemia without antiretro-
viral therapy following transplantation of stem cells from a
donor carrying the protective CCR5 Delta32/Delta32 deletion
[4]. This failure to reach a cure for HIV was described as
primarily due to the absence of eradication of any trace of
replication-competent HIV DNA integrated into human cell
genomes [3].
Since the beginning of the HIV pandemic, 5–15% of
HIV-infected individuals have been identified as devoid of
clinical symptoms and progression in the absence of antiret-
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roviral treatment [5,6]. Some of them, representing <1% of
HIV-positive persons, exhibit spontaneous control of HIV
replication, including the so-called ‘elite controllers’ (ECs),
who spontaneously and durably exhibit undetectable or almost
undetectable virus in plasma and a normal CD4-cell count
[6,7]. ECs attracted attention and sparked research to identify
the factors associated with spontaneous functional cure of HIV
infection. Various potential mechanisms involving viral, host
genetic and immunological patterns were identified, but none
of them could explain the spontaneous control of HIV
replication alone or in all of the cases [5–8].
We investigated here a patient who had been HIV-sero-
positive since 1985 with asymptomatic infection in the absence
of antiretroviral treatment and no detectable infectious virus
nor any HIV RNA or DNA genomic material retrieved from
the plasma or peripheral blood mononuclear cells (PBMCs),
and who thus appeared to be cured. We studied in depth his
host response and searched for any trace of HIV DNA
integrated into PBMCs. In addition, we searched for other
similar cases in our series.
Methods
Patients
Our patient cohort was composed of 1700 HIV-infected
patients, including ten elite HIV-1 controllers. Among these
ten, two also had undetectable PBMC HIV DNA; they gave
their written informed consent to be included in the study.
Host testing
Anti-HIV-1 antibody testing was performed using an
enzyme-linked immunosorbent assay (Architect; Abbott
Diagnostics, Mannheim, Germany) and Western blot testing
(Bio-Rad, Stanford, CA, USA). Analysis of plasma tryptophan
(W) levels was performed using the 7300 High Performance
Amino Acid Analyzer (Beckman Instruments, Inc., Fullerton,
CA, USA). APOBEC mRNA quantification in the PBMCs
was performed. The sequence of gene encoding the CCR5
chemokine receptor and HLA genotype were determined.
Resistance of the PBMCs to HIV super infection was
assessed by inoculating these PBMCs with HIV-1 strain
NL4.3. To test the inhibitory effect of the two case-patients’
sera on HIV growth, the NL4.3 strain was cultured on
control PBMCs in the presence of 100 µL of these sera or
control sera (see Supporting information).
Immunological investigations
For flow cytometry analyses, PBMCs were stained with the
following monoclonal anti-human antibodies used in various
combinations: CD3, CD4, CD38, HLADR, CCR7, granzyme B,
perforin, TNFa, IFNc and MIP1b (BD Biosciences, San Jose,
CA, USA); CD8 and CD45 RA (eBioscience, San Diego, CA,
USA). To study HIV-specific T-cell responses, PBMCs were
cultured in the presence of HIV-specific antigens consisting of a
mix of 15-mers overlapping 11-amino acid peptides (36
peptides in Gag, Pol and Nef sequences). On day 2, 100 U/
mL recombinant IL-2 (Miltenyi Biotec, Bergisch Gladbach,
Germany) was added, then cells were harvested on day 7, and
re-stimulated with the same pool of peptides for 6 hours in
the presence of anti-CD28/anti-CD49d co-stimulatory anti-
bodies and Golgi Plug (BD Biosciences). Thereafter, cells were
stained for intracytoplasmic cytokines (TNFa, IFNc and
MIP1b) (see Supporting information).
Virological investigation
Culture assays. Culture assays were performed as described
previously [9] and in the Supporting information.
HIV nucleic acid and protein detection. Routine plasma HIV
RNA testing was performed using the RealTime HIV-1 assay
(Abbott Diagnostics) and the Generic HIV-RNA assay
(Biocentric, Bandol, France) (detection limit, 40 and 300
copies/mL, respectively). Total (integrated and unintegrated)
cell-associated HIV DNA testing was performed as previ-
ously described (detection limit, 20 copies/106 PBMCs) [10].
HIV protein identification in serum was performed by
immunoprecipitation with anti-HIV P24 monoclonal mouse
antibodies using magnetic beads coupled with protein A
(Dynabeads Technology, Invitrogen, Carlsbad, CA, USA).
The precipitate was separated by SDS-PAGE and analysed
using MALDI-TOF mass spectrometry and a search in viral
protein databases (see Supporting information).
HIV genome sequencing and analyses. HIV genome sequencing
was performed using Sanger population and next-generation
sequencing of HIV-1 DNA from the two case-patients’
PBMCs and, to obtain missing fragments of the HIV genome,
a new procedure named the ‘Bortsch’ procedure. HIV
sequences obtained from the two case-patients are available
from GenBank with accession numbers KM878756-810 and
KM878811-833. Phylogenetic analyses and subtyping are
described in the Supporting information. HIV genomes from
ECs and non-ECs were searched for in GenBank (http://
www.ncbi.nlm.nih.gov/nuccore/), and retrieved genomes
were compared with those from the two case-patients,
seeking stop codons, hypermutations, insertions/deletions
and other mutations in each HIV-1 protein sequence. For
comparison of the W-to-stop mutations in ECs and
non-ECs, hypermutated genomes from the Eyzaguirre et al.
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(a)
(b)
(c)
FIG. 1. (a) Western blot HIV-1 for
serum samples from the two
case-patients. Values near the Western
blot indicate the ratio between the signal
obtained for the band compared to that
from the positive control (see Supporting
information). CA, capside; Env, envelope;
gp, glycoprotein; IN, integrase; MA,
matrix; Pos., positive control; Neg.,
negative control; su, subunit; RT, reverse
transcriptase. (b) Seroneutralization by
the case-patients’ serum of infection of
peripheral blood mononuclear cells from
HIV-negative donors by HIV-1 strain
NL4.3. Ct, PCR cycle threshold; PBMCs,
peripheral blood mononuclear cells. (c)
Infectability of peripheral blood
mononuclear cells from case-patients by
the HIV-1 strain NL4.3. Ct, PCR cycle
threshold; PBMCs, peripheral blood
mononuclear cells.
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study [11] were used, the sequence of each gene being
translated then aligned to detect stop codons (see Support-
ing information).
Results
The index case is a 57-year-old patient who heavily used
intravenous drugs between 1978 and 1988. He was diagnosed
HIV-positive in 1985 and did not suffer from any clinical
manifestations linked to HIV infection. He claimed to exhibit a
special immunity, presenting no fever or lymphadenopathy
during his life. His CD4-cell count was always normal (CD4-
and CD8-cell counts were 1576 and 1234, respectively) and no
HIV RNA was ever found in his plasma nor HIV DNA in his
PBMCs. In contrast, he suffered from active hepatitis C
infection. He was continuously exposed to HIV as his wife
shared syringes with him until 1988; she was diagnosed
HIV-positive in 1985 and developed AIDS with a different virus
(see Supporting information). This patient’s resistance to HIV
justified an in-depth investigation of both his host response and
his integrated retrovirus.
Strong reactivity against all tagged proteins was noted on
the Western blot (Fig. 1a). No homozygosity or heterozygos-
ity for the 32-base pair (bp) deletion in the CCR5 co-receptor
gene was found. HLA genotype is not associated with HIV
protection. The serum of the patient was found to protect
HIV-negative PBMCs from the virulent HIV-1 strain NL4.3
(Fig. 1b and Supporting information). This was also observed
for three out of eight sera from HIV-positive controls but not
for sera from the HIV-negative controls, indicating that NL4-3
can be neutralized by some HIV-positive sera [12]. Moreover,
an attempt to obtain an infection of the PBMCs from this
patient with the same virulent strain was unsuccessful (Fig. 1c),
although this does not allow speculation on susceptibility to
other HIV strains. We conclude that this patient was immune
to super infection with HIV. We were unable to grow HIV
from this patient but we detected in his serum three viral
peptides with similarities to HIV-1 reverse transcriptase (see
Supporting information). Sequencing the HIV DNA integrated
into the PBMCs of the patient was extremely laborious
because of the very low copy number (<20 copies/106 PBMCs),
but we obtained a 9302-bp-long subtype B HIV genomic
sequence using Sanger population, clonal sequencing and
next-generation sequencing (Fig. 2) (see Supporting informa-
tion). Surprisingly, we found many stop codons, all at W codon
(TGG) positions, reaching 25% of the 92 W codons of the
whole genome and 100% in three HIV genes (Fig. 2, Table 1
and Supporting information, Table S1). Therefore, we con-
cluded that the virus was inactivated and the patient was cured.
FIG. 2. HIV genome retrieved from
case-patient no. 1. HIV genes are shown
on the outer ring. On the inner rings, blue
lines indicate tryptophan (W) codons in
genes; red lines indicate W-to-stop
mutations. Representation was built using
DNAplotter (http://www.sanger.ac.uk/
Software/Artemis/circular/).
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The second patient in our cohort was also considered to be
an HIV EC with no detectable RNA or DNA using standard
methods. This 23-year-old homosexual Chilean man was
identified as HIV-infected in 2011 and most likely infected in
Chile during the 3 previous years, and his HIV sequence was
clustered with South American viral genomes (see Supporting
information). His serum showed weak anti-HIV reactivities on
the Western blot (Fig. 1a). T-cell phenotypic characteristics of
the patient, including frequency of different T-cell subpopula-
tions and the activation or cytotoxic marker expression by
CD4 and CD8 T-cells, did not differ from those of an
HIV-infected control patient (Fig. 3a). Despite a low CD8+
T-cell response, this patient exhibited high CD4+
T-cell responses in terms of cytokine production (42.8%,
37.9% and 40.1% of CD4+ T-cell-producing IFN-c, TNF-a and
MIP1b, respectively) compared with a group of 22 HIV
controls (mean  standard deviation (SD) = 5.5  14.4%,
4.5  10.2% and 5.9  15.5%) (Y. Levy, personal data)
(Fig. 3b). Serum from this patient did not inhibit HIV infection,
and his PBMCs were susceptible to infection by the NL4.3
strain (Fig. 1b-c; see Supporting information). This patient did
not harbour homozygosity/heterozygosity for the 32-bp
deletion in the CCR5 co-receptor gene and his HLA genotype
is not HIV protective. HIV co-culture was unsuccessful. HIV
genome sequencing from the patient’s PBMCs showed that he
exhibited 21 stop codons, with all but two being located at W
codons (Tables 1 and S1).
When comparing the distribution of stop codons replacing
W, in case-patient 1, the accessory and regulatory genes vif,
vpr, vpu and tat were mostly affected (≥50 to 100% of
W-to-stop mutations in these genes), whereas in case-patient
2, only the gag, pol, env and nef genes were affected
(Supporting information, Table S1). We then compared the
HIV genomes from ECs and non-ECs. The median rate of
W-to-stop mutations was significantly higher in ECs (including
the two present cases) than in non-ECs (20 vs. 9; p < 0.001;
Mann-Whitney test) (Supporting information and Table S1). In
addition, this mutation was present at 16 particular W codons
only in the ECs, and at codons 38 in vpr and 840 in env only in
our two case-patients.
Discussion
The two case-patients studied here are apparently cured of
their HIV infection and one exhibits cells resistant to HIV
infection in vitro. Functional cure, as defined by spontaneous
control of HIV infection without disease progression, was
therefore achieved [13]. This occurred despite HIV DNA
sequences could be laboriously retrieved from PBMCs.T
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Research into a cure for HIV currently aims to remove any
trace of HIV DNA from human cells, including through
‘purging’ of the latent HIV reservoir [3,13]. In contrast, we
believe that the persistence of HIV DNA can lead to cure, and
protection, from HIV. Globally, protection acquired by pop-
ulations against viral infections was very commonly through
integration of the infecting virus sequences and endogeniza-
tion, as now also clearly described for bacteria and archaea
with the CRISPR-Cas systems [14]. Retrovirus endogenization
corresponds to retroviral DNA integration into germ cells,
which allows its vertical transmission [15]. Endogenous
retroviruses (ERV) are present in genomes from many
mammals, including in humans; 8% of the genetic sequences
of modern man are retroviral sequences, corresponding to
100 000 ERV [16,17]. The most famous ERV genes encode
syncytins, which allowed syncytiotrophoblast formation in
mammalian placentas [18]. Recently, retrovirus endogenization
was highlighted as on-going in koala populations [19,20]. These
findings suggest that without therapeutic and prophylactic
strategies, after several decades of HIV/host interactions and
millions of deaths, it is likely that a few individuals might have
endogenized and neutralized the virus and transmitted it to
their progeny. In fact, given our difficulties in obtaining HIV
sequences from the two case-patients, we speculate that this
phenomenon may be much more common than observed in
sequence databases, and that HIV cure may have already
occurred through endogenization, in default of occurring
through HIV ‘reservoir’ eradication [3]. Massive sequencing in
the near future of human DNA, including from African native
individuals more extensively and anciently exposed to HIV,
may reveal traces of such HIV endogenization processes.
Duration of endogenization at the individual level is unknown.
Several mechanisms of resistance to HIV have been
described [6,21]. Those involved in resistance to HIV super
infection observed in case-patient 1 may include resistance
conferred by integrated HIV DNA. Thus, resistance to
exogenous retroviruses conferred by related ERV has been
reported, which can include blocking of entry receptors or
cell budding [22,23]. Regarding differences between anti-HIV
immune responses observed on Western blotting for the
two case-patients’ sera, they may be related to different
mechanisms of the endogenization process. Reactivities are
weaker and fewer for case-patient 2, but this patient exhibits
strong CD4+ T-cell responses. In addition, some viral
(a) (b)
FIG. 3. Flow cytometric profiles of T cells of case no. 2. (a) Ex vivo phenotype of T cells. Differentiation (CD45RA, CCR7), activation (CD38,
HLADR) and cytotoxic (Granzyme B, Perforin) markers were used to analyse CD4 (upper panel) and CD8 (lower panel) T cells. (b) Intracellular
cytokine staining after 8 days of PBMC culture with a pool of 36 HIV-1 peptides. HIV-specific CD4+ (upper panel) and CD8+ (lower panel) T cells
able to produce IFNc, TNFa and/or MIP1b. Plots are gated on viable CD3+ CD4+ or CD4+CD8+ T cells, respectively.
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APOBEC3G
•hyperactive, or 
• resistant to Vif, or  
• in Vif-deficient HIV
Hypermutations G A at W codons: 
W (TGG) Stop ( )
Vif
(non-functional)
Infectious virus
Non-infectious virus
Non-functional
viral proteins 
CD4 cell 
No viral production
or
APOBEC3G
(a)
Vif
(non-functional)
Non-infectious virus 
Non-functional
viral proteins 
CD4 cell 
No viral production
or
DNA pol
(c)
Vif
(non-functional)
Infectious virus  
Non-infectious virus 
Non-functional
viral proteins 
CD4 cell 
No viral production
or
RNA pol
(b)
FIG. 4. Schematic of hypotheses for
tryptophan (W)-to-stop codon mutations,
and HIV cure, in the two case-patients.
W-to-stop codonmutationsmayoccur due
to increasedAPOBEC3G activity (including
that mediated, or boosted, by vif gene
knockout) (a), errors of the cellular RNA
polymerase (b) or DNA polymerase (c).
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proteins are still produced and may play a role in the
maintenance of T-cell immunity detected after cell stimulation
in vitro [24].
In our case-patients, we suspect that knock out (KO) of the
viral genes by replacing a W codon by a stop codon is the key
to understanding the viral neutralization. Indeed, between 16
and 24 W-to-stop mutations, including at positions only
observed in ECs, were observed in HIV sequences [11]. The
reason for these KO mutations is not established (Fig. 4). It
may be that the patients’ DNA or RNA polymerases are prone
to errors that are not fatal for the patient’s health. In any case,
these patients had normal W levels in their blood. The best
candidates are APOBEC proteins, and specifically APOBEC3G,
which enters the virion and changes G to A [25], as observed
here, and is thought to represent an ancient strategy of
defence against ERV in humans [26]. These proteins may be
more expressed or active in the two case-patients, which was
not demonstrated here. Otherwise, APOBEC3G activity may
have been temporarily boosted by interferon-alpha adminis-
tered to the index case for his chronic hepatitis C [24,27]. In
addition, a recent study suggests that co-infection with
Streptococcus may enhance the activity of these proteins and
inhibit HIV growth by generating hypermutability [28]. The Vif
protein theoretically blocks APOBEC3G activity [29]. As the
Vif encoding gene is KO at a functionally critical position (21)
[30] in case-patient 1, this is likely to have contributed to the
extensive inactivation of the HIV genome.
The phenomenon of HIV gene inactivation that precludes
the production of replication-competent viruses has been
previously reported by several teams, including recently by
Eyzaguirre et al. [11], who stated that some of their patients
had defective proviral genomes. What we searched for and
found here were HIV-infected patients with integrated viral
DNA in their genomes but no HIV production. We do not
believe that our two case-patients are unique, or the
phenomenon described here is new. In contrast, our
approach largely differs from earlier ones, as we suggest
that persistence of integrated HIV DNA is not a barrier, but
on the contrary, may be a prerequisite for HIV cure.
Therefore, we propose a new vision of HIV cure through
integration, inactivation and potential endogenization of a
viral genome into the human genome. Finally, we believe that
potential mechanisms of the natural cure of or resistance to
HIV through persistence of integrated defective HIV DNA
and endogenization are a critical model to develop preventive
and curative strategies. We suggest that testing the occur-
rence of stop codons in the DNA of the integrated HIV
(including the two signatures in the vpr and env genes) may
predict the control and/or cure of the disease. This is critical
because, for all patients being treated, the natural resistance
will no longer be apparent. In conclusion, our findings, which
warrant further confirmation, are a first step in understand-
ing the resistance to retroviruses. They may allow us to
figure out the endogenization of retroviruses and detect
resistant patients, as well as to initiate strategies that imitate
these patients in order to cure or prevent AIDS.
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